MML Investors Services LLC Reduces Stock Position in DexCom, Inc. (NASDAQ:DXCM)

MML Investors Services LLC reduced its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 52.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,975 shares of the medical device company's stock after selling 34,502 shares during the period. MML Investors Services LLC's holdings in DexCom were worth $2,077,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the business. Blue Trust Inc. increased its stake in DexCom by 128.8% during the 2nd quarter. Blue Trust Inc. now owns 881 shares of the medical device company's stock valued at $100,000 after purchasing an additional 496 shares in the last quarter. Hennion & Walsh Asset Management Inc. lifted its position in DexCom by 135.4% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 3,830 shares of the medical device company's stock valued at $434,000 after acquiring an additional 2,203 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in DexCom by 15.3% during the 2nd quarter. Nisa Investment Advisors LLC now owns 68,460 shares of the medical device company's stock valued at $7,762,000 after purchasing an additional 9,092 shares during the last quarter. Apollon Wealth Management LLC increased its holdings in shares of DexCom by 0.7% in the 2nd quarter. Apollon Wealth Management LLC now owns 22,143 shares of the medical device company's stock worth $2,511,000 after purchasing an additional 163 shares in the last quarter. Finally, First Horizon Advisors Inc. raised its stake in shares of DexCom by 46.4% in the second quarter. First Horizon Advisors Inc. now owns 1,467 shares of the medical device company's stock worth $166,000 after purchasing an additional 465 shares during the last quarter. Institutional investors own 97.75% of the company's stock.

Insider Transactions at DexCom

In other DexCom news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the transaction, the executive vice president now owns 71,192 shares in the company, valued at $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.30% of the company's stock.

DexCom Trading Up 1.8 %

NASDAQ:DXCM traded up $1.39 during midday trading on Tuesday, hitting $77.80. The stock had a trading volume of 3,613,551 shares, compared to its average volume of 3,884,019. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The stock has a 50-day moving average of $74.08 and a 200 day moving average of $83.46. The company has a market capitalization of $30.39 billion, a price-to-earnings ratio of 46.59, a PEG ratio of 2.46 and a beta of 1.12. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00.

Analyst Upgrades and Downgrades

DXCM has been the subject of several research analyst reports. Citigroup lifted their price objective on DexCom from $85.00 to $91.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. Piper Sandler reissued an "overweight" rating and set a $90.00 price objective on shares of DexCom in a report on Monday, August 26th. Leerink Partners dropped their target price on shares of DexCom from $90.00 to $87.00 and set an "outperform" rating on the stock in a report on Friday, October 25th. StockNews.com lowered shares of DexCom from a "buy" rating to a "hold" rating in a research note on Saturday, November 2nd. Finally, Oppenheimer dropped their price target on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research note on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, DexCom currently has a consensus rating of "Moderate Buy" and an average price target of $98.00.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.